Download PDF
CC BY-NC-ND 4.0 · European Journal of General Dentistry 2019; 8(01): 1-6
DOI: 10.4103/ejgd.ejgd_137_18
Review Article

Inspecting evidence between cancer therapy-induced oral mucositis and periodontitis: A narrative review

Cristina De Paula Novaes
Department of Clinical Dentistry, School of Dentistry, Federal University of Juiz De Fora, Juiz De Fora, MG, Brazil
,
Aline Moreira
Department of Clinical Dentistry, School of Dentistry, Federal University of Juiz De Fora, Juiz De Fora, MG, Brazil
,
Maria Das Graças Afonso Miranda Chaves
Department of Clinical Dentistry, School of Dentistry, Federal University of Juiz De Fora, Juiz De Fora, MG, Brazil
,
Gisele Maria Campos Fabri
Department of Clinical Dentistry, School of Dentistry, Federal University of Juiz De Fora, Juiz De Fora, MG, Brazil
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

This narrative review aims to update the reader about the current issues surrounding central aspects implicated in the relationship between oral mucositis (OM) and periodontitis. We searched Medline/PubMed database. English language publications were included in the study. Paired reviewers selected articles for inclusion and extracted data. Forty-four studies met our inclusion criteria. The majority of the studies were review (63.8%) and clinical studies (36.2%). There is a lack of studies regarding the association of periodontal disease (PD) and OM. However, there are pathogenic similarities between them. Look for scientific evidence to confirm the relationship between PD and OM is imperative. Thus, if periodontitis can actually interfere with the occurrence and severity of OM, the establishment of strategies to reduce it may contribute to better control of OM, a serious adverse effect of cancer treatment.

Keywords

Cancer therapy - oral mucositis - periodontitis

Financial support and sponsorship

Nil.




Publication History

Article published online:
01 November 2021

© 2019. European Journal of General Dentistry. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Villa A, Sonis ST. Mucositis: Pathobiology and management. Curr Opin Oncol 2015;27:159-64.
  • 2 Chaudhry HM, Bruce AJ, Wolf RC, Litzow MR, Hogan WJ, Patnaik MS, et al. The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: A systematic review. Biol Blood Marrow Transplant 2016;22:605-16.
  • 3 Chaveli-López B, Bagán-Sebastián JV. Treatment of oral mucositis due to chemotherapy. J Clin Exp Dent 2016;8:e201-9.
  • 4 Bartold PM, Cantley MD, Haynes DR. Mechanisms and control of pathologic bone loss in periodontitis. Periodontol 2000 2010;53:55-69.
  • 5 Lima HG, Lara VS. Immunological Aspects of Inflammatory Periodontal Disease: Involvement of Mast Cells. Cient Cienc Biol Saude 2013;15:225-9.
  • 6 Chapple IL, Genco R; Working Group 2 of the Joint EFP/AAP Workshop. Diabetes and periodontal diseases: Consensus report of the joint EFP/AAP workshop on periodontitis and systemic diseases. J Periodontol 2013;84:S106-12.
  • 7 Mombelli A. Microbial colonization of the periodontal pocket and its significance for periodontal therapy. Periodontol 2000 2018;76:85-96.
  • 8 Ohlrich EJ, Cullinan MP, Seymour GJ. The immunopathogenesis of periodontal disease. Aust Dent J 2009;54 Suppl 1:S2-10.
  • 9 van der Velden WJ, Herbers AH, Netea MG, Blijlevens NM. Mucosal barrier injury, fever and infection in neutropenic patients with cancer: Introducing the paradigm febrile mucositis. Br J Haematol 2014;167:441-52.
  • 10 Lindhe J, Lang NP, Karring T. Clinical periodontology and implant dentistry, 5th ed. Oxford: Wiley-Blackwell; 2008.
  • 11 Di Benedetto A, Gigante I, Colucci S, Grano M. Periodontal disease: Linking the primary inflammation to bone loss. Clin Dev Immunol 2013;2013:503754.
  • 12 Krauss JL, Potempa J, Lambris JD, Hajishengallis G. Complementary tolls in the periodontium: How periodontal bacteria modify complement and toll-like receptor responses to prevail in the host. Periodontol 2000 2010;52:141-62.
  • 13 Socransky SS, Haffajee AD. Periodontal microbial ecology. Periodontol 2000 2005;38:135-87.
  • 14 Kinane DF, Zhang P, Benakanakere M, Singleton J, Biesbrock A, Nonnenmacher C, et al. Experimental gingivitis, bacteremia and systemic biomarkers: A randomized clinical trial. J Periodontal Res 2015;50:864-9.
  • 15 Graves DT, Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol 2003;74:391-401.
  • 16 Benakanakere M, Kinane DF. Innate cellular responses to the periodontal biofilm. Front Oral Biol 2012;15:41-55.
  • 17 Kornman KS. Mapping the pathogenesis of periodontitis: A new look. J Periodontol 2008;79:1560-8.
  • 18 Kinane DF, Peterson M, Stathopoulou PG. Environmental and other modifying factors of the periodontal diseases. Periodontol 2000 2006;40:107-19.
  • 19 Enwonwu CO, Salako N. The periodontal disease-systemic health-infectious disease axis in developing countries. Periodontol 2000 2012;60:64-77.
  • 20 Fernandes EG, Savioli C, Siqueira JT, Silva CA. Oral health and the masticatory system in juvenile systemic lupus erythematosus. Lupus 2007;16:713-9.
  • 21 Savioli C, Silva CA, Fabri GM, Kozu K, Campos LM, Bonfá E, et al. Gingival capillary changes and oral motor weakness in juvenile dermatomyositis. Rheumatology (Oxford) 2010;49:1962-70.
  • 22 Savioli C, Ribeiro AC, Fabri GM, Calich AL, Carvalho J, Silva CA, et al. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis. J Clin Rheumatol 2012;18:180-4.
  • 23 Fabri GM, Siqueira SR, Simione C, Nasri C, Teixeira MJ, Siqueira JT, et al. Refractory craniofacial pain: Is there a role of periodontal disease as a comorbidity? Arq Neuropsiquiatr 2009;67:474-9.
  • 24 de Souza Rolim T, Fabri GM, Nitrini R, Anghinah R, Teixeira MJ, de Siqueira JT, et al. Oral infections and orofacial pain in Alzheimer’s disease: A case-control study. J Alzheimers Dis 2014;38:823-9.
  • 25 Fabri GM, Savioli C, Siqueira JT, Campos LM, Bonfá E, Silva CA. Periodontal disease in pediatric rheumatic diseases. Rev Bras Reumatol 2014;54:311-7.
  • 26 Takakubo Y, Konttinen YT. Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases. Clin Dev Immunol 2012;2012:941346.
  • 27 Turner L, Mupparapu M, Akintoye SO. Review of the complications associated with treatment of oropharyngeal cancer: A guide for the dental practitioner. Quintessence Int 2013;44:267-79.
  • 28 Fadda G, Campus G, Lugliè P. Risk factors for oral mucositis in paediatric oncology patients receiving alkylant chemotherapy. BMC Oral Health 2006;6:13.
  • 29 Pinto MTF, Soares LG, da Silva DG, Tinoco EMB, Falabella MEV. Prevalence of oral manifestations in children and young patients submitted to chemotherapy. Prevalence of oral manifestations in children and young patients submitted to chemotherapy. Rev Pesqui Saúde 2013;14:45-8.
  • 30 Carvalho PA, Jaguar GC, Pellizzon AC, Prado JD, Lopes RN, Alves FA, et al. Evaluation of low-level laser therapy in the prevention and treatment of radiation-induced mucositis: A double-blind randomized study in head and neck cancer patients. Oral Oncol 2011;47:1176-81.
  • 31 Hespanhol FL, Tinoco EM, Teixeira HG, Falabella ME, Assis NM. Buccal manifestations in patients submitted to chemotherapy. Ciênc Saúde Colet 2010;15:1085-94.
  • 32 Coracin FL, Santos PS, Gallottini MH, Saboya R, Musqueira PT, Barban A, et al. Oral health as a predictive factor for oral mucositis. Clinics (Sao Paulo) 2013;68:792-6.
  • 33 Gussgard AM, Hope AJ, Jokstad A, Tenenbaum H, Wood R. Assessment of cancer therapy-induced oral mucositis using a patient-reported oral mucositis experience questionnaire. PLoS One 2014;9:e91733.
  • 34 Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100:1995-2025.
  • 35 Parulekar W, Mackenzie R, Bjarnason G, Jordan RC. Scoring oral mucositis. Oral Oncol 1998;34:63-71.
  • 36 Raber-Durlacher JE, Epstein JB, Raber J, van Dissel JT, van Winkelhoff AJ, Guiot HF, et al. Periodontal infection in cancer patients treated with high-dose chemotherapy. Support Care Cancer 2002;10:466-73.
  • 37 Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002;34:1524-9.
  • 38 Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007;33:448-60.
  • 39 Janket SJ, Baird AE, Chuang SK, Jones JA. Meta-analysis of periodontal disease and risk of coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:559-69.
  • 40 Cullinan MP, Ford PJ, Seymour GJ. Periodontal disease and systemic health: Current status. Aust Dent J 2009;54 Suppl 1:S62-9.
  • 41 Khaw A, Logan R, Keefe D, Bartold M. Radiation-induced oral mucositis and periodontitis-proposal for an inter-relationship. Oral Dis 2014;20:e7-18.
  • 42 Albuquerque ILS, Camargo TC. Prevention and treatment of radiotherapy-induced oral mucositis: A literature review. Rev Bras Cancerol 2007;53:195-209.
  • 43 Santos PS, Coracin FL, Barros JC, Dulley FL, Nunes FD, Magalhães MG, et al. Impact of oral care prior to HSCT on the severity and clinical outcomes of oral mucositis. Clin Transplant 2011;25:325-8.
  • 44 Donnelly JP, Bellm LA, Epstein JB, Sonis ST, Symonds RP. Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect Dis 2003;3:405-12.